Enhancement of anticoagulant action by warfarin-benzbromarone interaction

Journal of Clinical Pharmacology

Volumn 36, Issue 2, 1996, Pages 168-174

  Shimodaira, Hideo ^a   Takahashi, Kiyoe ^a   Kano, Kimiko ^a   Matsumoto, Yusuke ^a   Uchida, Yutaka ^a   Kudo, Tatsuhiko ^b  

^a Hachioji Medical Center   (Japan)

^b TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BENZBROMARONE; BLOOD CLOTTING FACTOR 8; PROTHROMBIN; WARFARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; CLINICAL ARTICLE; DRUG EFFECT; DRUG SCREENING; FEMALE; GOUT; HUMAN; MALE;

EID: 0029925418     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1996.tb04182.x     Document Type: Article

References (24)

1. Toon S, Low LK, Gibaldi M, Trager WF, O' Reilly RA, Motley CH, Goulart DA: The warfarin-sulfinpyrazone interaction: stereochemical considerations. Clin Pharmacol Ther 1986;39:15-24.
2. Martin EW: Side Effects of Drugs in Clinical Practice. Second edition (Japanese translation by W Yoshitoshi. Tokyo, Japan: Hirokawa Shoten, 1384.
3. Sakuragawa N, Takahashi K, Nomura J, Sakashita I: Anticoagulant therapy. Nippon Ketsueki Gakkai Zasshi 1982;45:830-833.
4. Vesell ES, Passananti GT, Greene FE: Impairment of drug metabolism in man by allopurinol and nortriptyline. N EngJ J Med 1970;283:1484-1488.
5. Delbarre F, Auscher C, Amor B: Action uricosurique de certains dérivés du benzofuranne (letter). Bull Mem Soc Med Hop Paris 1965;116:1193.
6. Politta G, Berthoud S, Gaudin G, Chavaz A, Fabre J: Mécanisme de l'action uricosurique de la benzbromarone. Schweiz Rundsch Med Prax 1973;62:1345-1350.
7. Colin JN, Farinotti R, Fredj G, Tod M, Clavel JP, Vignon E, Dietlin F: Kinetics of allopurinol and oxipurinol after chronic oral administration: interaction with benzbromarone. Eur J Clin Pharmacol 1986;31:53-58.
8. Buisse JM, Demarez JP: Is there a drug interaction between allopurinol and benzbromarone (letter)? Presse Med 1986;15:716.
9. Müller FO, Schall R, Groenewoud G, Hundt HK, van der Merwe JC, van Dyk M: The effect of benzbromarone on allopurinol/oxypurinol kinetics in patients with gout. Eur J Clin Pharmacol 1993;44:69-72.
10. Owren PA. Thrombotest, a new method for controlling anticoagulant therapy. Lancet 1959;2:752-754.
11. Dati F, Barthels M, Conard J, Flückiger J, Girolami A, Hänseler E, et al: Multicenter evaluation of a chromogenic substrate method for photometric determination of prothrombin time. Thromb Haemost 1987;58:856-865.
12. Sakurabayashi I, Kawai T, Omizo R, Hattori N, Ishii M: Fundamental Studies, reference values, and clinical evaluation of abnormal prothrombin PIVKA-II assay using monoclonal antibody (E-1023). Rinsho Byori 1988;36:1407-1412.
13. Steyn JM, van der Merwe HM, de Kock MJ: Reversed-phase high-performance liquid chromatographic method for the determination of warfarin from biological fluids in the low nanogram range. J Chromatogr 1986;378:254-260.
14. Hadama T, Takasaki H, Mori Y, Oka K, Shigemitu O, Fujishima K, et al: A study on optimization of coagulative function by warfarin and antiplatelet agents in patients with prosthetic valve replacement (in Japanese). J Jpn Cardiovasc Surg Assoc 1990;19: 1264-1266.
15. Vigano S, Mannucci PM, Solinas S, Bottasso B, Mariani G: Decrease in protein C antigen and formation of an abnormal protein soon after starting oral anticoagulant therapy. Br J Haematol 1984;57:213-220.
16. van der Klauv MM, Houtman PM, Stricker BH: Hepatic injury caused by benzbromarone. J Hepatol 1994;20:376-379.
17. Berg H: Effectiveness and tolerance of long-term uricosuric treatment. Z Gesamte Inn Med 1990;45:719-720.
18. Walter-Sack I, Vries JX, Ittensohn A, Kohlmeier M, Weber E: Benzbromarone disposition and uricosuric action: evidence for hydroxilation instead of debromination to benzarone. Klin Wochenschr 1988;66:160-166.
19. Arnold PJ, Guserle R, Luckow V, Hemmer R, Grote H: Liquid chromatography-mass spectrometry in metabolic research. I. Metabolites of benzbromarone in human plasma and urine. J Chromatogr 1991;554:267-280.
20. Lewis RJ, Trager WF, Chan KK, Breckenridge A, Ormen M, Roland M, Schary W: Warfarin: stereochemical aspects of its metabolism and the interaction with phenylbutazone. J Clin Invest 1974;53:1607-1617.
21. O'Reilly RA, Aggeler PM, Hoag MS Leong L: Studies on the coumarin anticoagulant drugs: assay of warfarin and its biologic application. Thromb Diathesis Haemorrhagica 1962:8;82-95.
22. Witing J, von der Giesen WF, Janssen LHM, Weideman MM, Otagiri M, Perrin JH: The effect of albumin conformation on the binding of warfarin to human serum albumin. J Biol Chem 1980;255:3032-3037.
23. Walter Sack I, de Vries JX, Ittensohn A, Weber E: Rapid and slow benzbromarone elimination phenotypes in man: benzbromarone and matabolite profiles. Eur J Clin Pharmacol 1990;39: 577-581.
24. Gresser U, Adjan M, Zollner N: Deficient benzbromarone elimination from plasma: evidence for a new genetically determined polymorphism with an autosomal recessive inheritance. Adv Exp Med Biol 1991; 309A(suppl):157-160.